Nadezhda V. Suvorova

Nadezhda V. Suvorova

Auto-generated profile, based on publicly available information

Nadezhda V. Suvorova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2024 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
AVA. O. Vereshchagina
A. O. Vereshchagina
GSGalina Solopova
Galina Solopova
TBT. A. Bykova
T. A. Bykova
MPMarina Popova
Marina Popova
DBD. N. Balashov
D. N. Balashov
GNG. A. Novichkova
G. A. Novichkova
The clinical course of the novel coronavirus disease (COVID-19) in patients with oncological and hematological diseases after hematopoietic stem cell transplantation (HSCT), are of special interest. To further investigate the problem, a two-center study was undertaken at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and the R.M. Gorbacheva National Research Institute for Pediatric Oncology, Hematology and Transplantation between January 2020 and January 2023. This was a retrospective-prospective, non-randomized, non-interventional study that included children aged 0–19 years with oncological and hematological diseases and primary immunodeficiencies who had undergone allogeneic HSCT and subsequently contracted COVID-19. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. COVID-19 cases were confirmed by polymerase chain reaction testing and classified as asymptomatic, mild, moderate, severe, and critical. The study included 105 patients with a median age of 9 years; male patients were predominant (the male-to-female ratio was 1.8:1). The primary diseases were hematological malignancies (73%), benign hematological diseases (14%) and primary immunodeficiencies (13%). The most common clinical symptoms of COVID-19 were fever, gastrointestinal symptoms, and respiratory symptoms; 40% of COVID-19 cases were asymptomatic. Lymphopenia was found to be a risk factor for severe COVID-19. The patients without immune reconstitution had a longer persistence of the COVID-19 virus than those with immune reconstitution (17 days versus 13 days), however, no significant differences were obtained (p = 0.7). There were also no significant differences in the severity and outcomes of COVID-19 between the patients with immune reconstitution and those without reconstitution. There was no effect of therapy on the duration of COVID-19, and there was no association between the type of treatment and the duration of the disease. The overall survival rate in the allo-HSCT recipients who had been diagnosed with COVID-19 was 88%, which was lower than in the non-recipients (88% vs 94%; p = 0,077).

14 May 2026 in Tuberculosis and Lung Diseases
Verified
Journal Article
Closed access
VRV. A. Romanenko
V. A. Romanenko
NKN. I. Klevno
N. I. Klevno
AKAlexey Владимирович Kazakov
Alexey Владимирович Kazakov
ESE. A. Sokolskaya
E. A. Sokolskaya
NSN. V. Suvorova
N. V. Suvorova
VAVasilyeva Irina Anatol'evna
Vasilyeva Irina Anatol'evna
The objective: to study detection and clinical and radiological characteristics of tuberculosis in children and adolescents with malignant diseases. Subjects and Methods. Medical records of 105 children with respiratory tuberculosis (RTB) aged from 6 months to 17 years inclusive, examined in 2018–2025, were analyzed. Children were divided into two groups: Main Group (MG) – children with respiratory tuberculosis (RTB) and malignant neoplasms (MN) (52 patients) and Control Group (CG) – children with RTB and no MN (53 patients). Demographic characteristics, features of clinical manifestations and forms of respiratory tuberculosis of the patients were retrospectively analyzed. Results. In 73.1% (38/52) of cases, respiratory tuberculosis in children from MG was detected during the onset of malignant neoplasms or their treatment, in 17.3% (9/52) – at the stage of malignant neoplasm remission, in 9.6% – at the stage of post-tuberculosis changes in the form of calcifications in the intrathoracic lymph nodes prior to development of malignant neoplasms. In MG, tuberculosis was detected in 59.6% (31/52) of patients with hemoblastoses and 40.4% (21/52) of patients with malignant neoplasms of solid organs. In children from MG, tuberculosis was detected in 21.2% (11/52) of cases based on the results of immunodiagnostics and in 78.8% (41/52) when they referred for help with complaints. In children from MG, the course of respiratory tuberculosis was characterized by a widespread disease (78.8%, 41/52) and development of bronchopulmonary complications (80.8%, 42/52). Among children with hemoblastoses, generalized or disseminated forms of tuberculosis were in 32.3% (10/31) of cases, in children with malignant neoplasms of solid organs – in 9.5% (2/21). The incidence of lesions of central nervous system in children from MG made 7.7% (4/52).

30 June 2026 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
GSGalina Solopova
Galina Solopova
СГСолопова Галина Геннадьевна
Солопова Галина Геннадьевна
LSL. N. Shelikhova
L. N. Shelikhova
ШНШелихова Л. Н.
Шелихова Л. Н.
ZMZh. V. Markova
Zh. V. Markova
НАНовичкова Г. А.
Новичкова Г. А.
Introduction. The rising incidence of mucormycosis among patients with hematologic and oncologic conditions has made it crucial to develop principles for the treatment of infectious complications as well as to assess the feasibility of allogeneic hematopoietic stem cell transplantation (HSCT) in this population. Aim: to analyze the specific aspects and safety of HSCT in children with mucormycosis. Materials and methods. This retrospective-prospective single-center study, conducted from 1 January 2013 to 31 March 2026 at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation, included HSCT recipients with a pre-transplant diagnosis of mucormycosis. The diagnostic work-up included computed tomography, magnetic resonance imaging, ultrasound, endoscopy, bronchoalveolar lavage, and biopsy of various organs and tissues depending on the site of involvement. From these specimens, slides were prepared in clearing solution supplemented with calcofluor white, a fluorescent agent. The slides were then examined under a fluorescence microscope using short-wavelength excitation at 400× magnification. Results. We analyzed treatment outcomes in 13 patients (median age: 11.7 years), 77% of whom had hematologic malignancies. At mucormycosis onset, pulmonary involvement was observed in 62% of the patients, paranasal sinus involvement in 54%; liver, spleen, and central nervous system involvement in 8%, and disseminated disease in 31%. Etiologic confirmation (77%) revealed Lichtheimia corymbifera (n = 2), Rhizomucor pusillus (n = 2), Rhizopus oryzae (n = 2), Rhizopus microsporus (n = 1), Mucor indicus (n = 1), and Mucor spp. (n = 2). All the patients received targeted antifungal therapy (amphotericin B, posaconazole, isavuconazole), with combination treatment used in 77% of cases. Surgical treatment was performed in 92% of the cases. Notably, radical resection significantly reduced the need for repeat surgeries (p = 0.02). Allogeneic HSCT was mostly performed using ex vivo αβ T-cell depletion (n = 11). At the time of transplantation, active infection was observed in 5 patients, partial response in 5 and complete response in 3. The median time to engraftment was 12 (10–35) days. Glucocorticoids for graft-versus-host disease were required in 3 patients. Mucormycosis was cured in 100% of cases. The median time to complete response was 82 days with early partial response (8 weeks) and 179 days with late response (p = 0.002). Infection status at HSCT did not affect the time to mucormycosis resolution. The overall survival was 59%, without any mucormycosis-associated deaths. Conclusion. The use of modern HSCT technologies (such as αβ T-cell depletion) in combination with aggressive antifungal treatment enables successful transplantation even in children with active mucormycosis.

29 January 2026 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
GSGalina Solopova
Galina Solopova
NSNadezhda V. Suvorova
Nadezhda V. Suvorova
AVAnastasia O. Vereshchagina
Anastasia O. Vereshchagina
ZMZhanna V. Markova
Zhanna V. Markova
AVAleksandr Voropaev
Aleksandr Voropaev
GNGalina A. Novichkova
Galina A. Novichkova
Over the past two decades, the incidence of rare invasive mycoses, including fusariosis, has increased. Fusariosis remains diagnostically challenging and is associated with high mortality. Here, we present the results of a retrospective-prospective single-center study conducted between 01.01.2013 and 01.11.2025 at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The study aimed to evaluate the clinical characteristics, diagnostic performance, and treatment outcomes of immunocompromised children with fusariosis. It included 16 patients (10 males and 6 females), the median age was 11.5 years (range 2.5–16.0). Hematological malignancies were present in 70% of the cases; primary immunodeficiency, aplastic anemia, osteosarcoma, and systemic lupus erythematosus were less common. Fusariosis developed after chemotherapy (n = 9), hematopoietic stem cell transplantation (n = 4), or immunosuppressive therapy (n = 3). The major risk factors included severe neutropenia and corticosteroid use (87.5%). Disseminated disease occurred in 50% of the patients, localized fusariosis was diagnosed in 40% of the patients, and isolated fungemia was reported in one case. The most frequently affected sites were skin/soft tissues (50%), paranasal sinuses (50%), and lungs (43.75%). Parenchymal organs, bones and eyes were involved less often. The main pathogens were Fusarium solani (n = 6) and Fusarium proliferatum (n = 5), followed by Fusarium oxysporum, Fusarium verticilioides, and Fusarium petroliphilum. Seven patients developed invasive fungal co-infections with Aspergillus flavus (n = 4), Rhizopus spp. (n = 1), Scedosporium aurantiacum (n = 1) and Candida glabrata (n = 1) which was associated with increased mortality. First-line therapy included lipid formulations of amphotericin B (81%) and voriconazole (56%); combination therapy was used in 62.5% of the cases. Fourteen patients achieved a rapid partial response (the median time to response was 21 days), which correlated with favorable outcomes: all these patients were cured and had significantly higher overall survival. In the entire cohort, the 6-week survival was 81%, the overall survival was 69%. The study demonstrated the effectiveness of timely diagnosis and specific therapy for invasive fusariosis in the most vulnerable category of immunocompromised children.